Rho Executive and Leadership Team

Lawrence Morentz, the Chief Executive Officer at Rho, directs the overarching corporate strategy and operational execution. Overseeing all business units, Morentz ensures alignment with the company's mission to provide comprehensive clinical research services. This leadership role involves guiding Rho's expansion within the drug development process, focusing on innovation and client success. By fostering strategic partnerships, Lawrence Morentz drives the company's growth and market position. The Chief Executive Officer's responsibilities include setting financial targets, managing key stakeholder relationships, and championing the company's culture of scientific excellence. Morentz's strategic vision shapes Rho's approach to navigating the complexities of clinical trials and regulatory environments, ultimately impacting the successful delivery of new therapies to market.

Michael Szarowicz, the Chief Financial Officer at Rho, manages all financial operations and fiscal strategy. Overseeing budgeting, forecasting, and financial reporting, Szarowicz ensures the company's financial health and sustainability. This critical role involves optimizing resource allocation across Rho's diverse clinical research services, supporting the entire drug development process. By implementing robust financial controls, Michael Szarowicz safeguards company assets and drives profitability. The Chief Financial Officer's duties extend to managing investor relations, securing funding for strategic initiatives, and analyzing market trends to inform financial planning. Szarowicz's expertise in financial management is essential for Rho's continued expansion and its ability to deliver complex research projects efficiently.

Alena Hammond, the Chief Operating Officer at Rho, directs the day-to-day operational activities and service delivery. Overseeing the execution of clinical research projects, Hammond ensures efficiency and quality across all phases of drug development. This leadership position involves optimizing operational workflows, managing cross-functional teams, and implementing best practices to enhance service delivery. By streamlining operational processes, Alena Hammond supports Rho's commitment to providing a full range of clinical research services. The Chief Operating Officer's responsibilities include driving operational excellence, managing vendor relationships, and ensuring compliance with industry regulations. Hammond's focus on operational effectiveness is vital for Rho's ability to meet client demands and achieve project milestones.

Mary Helms, the President & Co-Founder at Rho, provides foundational leadership and strategic vision for the organization. Overseeing key aspects of business development and company direction, Helms leverages extensive experience to guide Rho's growth and market presence. This leadership role involves fostering long-term client relationships and ensuring the company's services consistently meet evolving industry needs across the drug development spectrum. By championing Rho's core values, Mary Helms reinforces the company's commitment to scientific rigor and client success. The President & Co-Founder's responsibilities include strategic planning, representing the company externally, and driving initiatives that enhance Rho's reputation as a leading contract research organization. Helms's enduring dedication shapes Rho's legacy and future trajectory.

Deborah Johnson, the President at Rho, drives strategic initiatives and operational excellence across the organization. Overseeing key business functions, Johnson ensures the seamless delivery of comprehensive clinical research services that support the entire drug development lifecycle. This leadership position involves fostering innovation, optimizing resource allocation, and strengthening client partnerships to advance therapeutic breakthroughs. By focusing on strategic growth, Deborah Johnson enhances Rho's market position and its ability to tackle complex research challenges. The President's responsibilities include guiding departmental strategies, ensuring regulatory compliance, and promoting a culture of scientific integrity. Johnson's leadership is instrumental in maintaining Rho's reputation for quality and reliability in the contract research industry.

Biljana Djordjevic, the Technology Chief of Staff at Rho, supports the strategic direction and execution of technology initiatives. Overseeing technology project management and cross-departmental technology alignment, Djordjevic ensures that technological advancements enhance Rho's clinical research services. This role involves facilitating communication between technology teams and other business units, driving innovation in data management and analysis. By coordinating technology roadmaps, Biljana Djordjevic contributes to the efficient operation of the drug development process. The Technology Chief of Staff's responsibilities include managing technology budgets, evaluating new software solutions, and ensuring the security and integrity of company data. Djordjevic's focus on technology integration strengthens Rho's capabilities in delivering cutting-edge research solutions.

Andrew Feigin, the Chief Medical Officer at Rho, provides critical medical and scientific leadership for clinical research programs. Overseeing the medical strategy and scientific integrity of studies, Feigin ensures that Rho's services align with the highest standards of clinical practice and regulatory requirements. This pivotal role involves guiding the design and interpretation of clinical trials, contributing expertise to the entire drug development process. By offering deep medical insights, Andrew Feigin enhances the value and impact of Rho's research offerings. The Chief Medical Officer's responsibilities include advising on therapeutic areas, reviewing clinical data, and collaborating with clients on protocol development. Feigin's medical acumen is essential for advancing novel therapies and ensuring patient safety throughout clinical investigations.